XML 30 R24.htm IDEA: XBRL DOCUMENT v3.19.2
Shareholders' Equity (Tables)
6 Months Ended
Jun. 30, 2019
Stockholders' Equity Note [Abstract]  
Schedule of stock options activity
   Number of options   Weighted-average exercise price   Weighted- average remaining contractual term
(in years)
   Aggregate intrinsic value 
                 
Outstanding at January 1, 2019   415,510   $14,62    2.69   $       3 
Granted   -    -           
Exercised   (1,500)   6.00           
Expired and forfeited   (17,400)   15.99           
                     
Outstanding at June 30, 2019   396,610   $14.59    2.20   $2 
                     
Vested and expected to vest at June 30, 2019   396,610   $14.59    2.20   $2 
                     
Exercisable at June 30, 2019   230,884   $12.92    1.78   $2 
Schedule of stock options under 2013 share option plan
   Options outstanding at
June 30, 2019
   Options exercisable at
June 30, 2019
 
Exercise price  Number outstanding   Weighted average exercise price   Weighted average remaining contractual life   Number exercisable   Weighted average exercise price   Weighted average remaining contractual life 
$      $   In years       $   In years 
                         
6.00   750    6.00    0.06    750    6.00    0.06 
11.12-14.52   251,708    11.87    1.72    195,133    11.88    1.63 
18.90-19.85   144,152    19.39    3.05    35,001    18.90    2.64 
                               
    396,610              230,884           
Schedule of RSUs activity
   Number of RSUs   Weighted average remaining contractual term
(in years)
   Aggregate intrinsic value 
             
Outstanding at January 1, 2019   168,869    1.40   $1,253 
Granted   263,220           
Vested   (36,244)          
Cancelled and forfeited   (10,800)          
                
Outstanding at June 30, 2019   385,045    1.81   $3,169 
                
Vested and expected to vest at June 30, 2019   385,045    1.81   $3,169 
Schedule of departmental allocation of share-based compensation charge
   Six months ended
June 30,
 
   2019*   2018* 
   Unaudited 
         
Cost of revenues  $95   $77 
Research and development, net   357    411 
Sales and marketing   330    462 
General and administrative   183    392 
           
   $965   $1,342